Oncoinvent ASA Navne-Aksjer o.N.
- BID
7.72
- ASK
7.86
- 259 Units254 Units
- 07/21, 21:59:03 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
30.42%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-10.69 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 7.68 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:56:35 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 7.68 | 7.36 |
| PREV. DAY'S PRICE | 7.38 | (07/20) |
| CHANGE DAY BEFORE | +0.30 | 4.07 % |
| 52 WEEK HIGH / LOW | 560 (01/16) | 1.5 (01/02) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -74.75 | -21.77 | -10.69 | -3.69 | -1.49 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 5.86 | 2.61 | 1.50 | - | - |
PRICE - SALES RATIO | 1,124.02 | 340.33 | 2.64 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A41YN5 |
| ISIN | NO0013711713 |
| SYMBOL | 7BG |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ONCOINVENT ASA |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 20.98 % | 71.23 % | 68.49 % | 116.36 % | 30.42 % | -85.04 % | -99.51 % | 114.53 % |
| HIGH | 7.84 | 7.84 | 7.84 | 7.84 | 560.00 | 8,074.50 | 8,074.50 | 560.00 |
| LOW | 6.60 | 3.96 | 3.59 | 3.35 | 1.50 | 1.50 | 1.50 | 1.50 |
Dividende
pro Aktie
ONCOINVENT ASA does not deliver dividend information
Company profile
Oncoinvent ASA operates as a clinical-phase biotechnology company, which engages in the development of radiopharmaceutical treatment products for cancer therapy. Its focus product is Radspherin, which uses the alpha-emitting radionuclide radium-224 that targets residual micrometastases after surgery in the abdominal cavity. The company was founded by Roy H. Larsen, Øyvind Bruland, Dr. Tina Bønsdorff, and Dr. Thora Jonasdottir on December 21, 2007 and is headquartered in Oslo, Norway.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.